Trimazosin is a sympatholytic alpha-1 blocker.[1][2]

Trimazosin
Clinical data
ATC code
Identifiers
  • (2-Hydroxy-2-methylpropyl) 4-(4-amino-6,7,8-trimethoxyquinazolin-2-yl)piperazine-1-carboxylate
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.047.924 Edit this at Wikidata
Chemical and physical data
FormulaC20H29N5O6
Molar mass435.481 g·mol−1
3D model (JSmol)
  • O=C(OCC(O)(C)C)N3CCN(c1nc(N)c2c(n1)c(OC)c(OC)c(OC)c2)CC3
  • InChI=1S/C20H29N5O6/c1-20(2,27)11-31-19(26)25-8-6-24(7-9-25)18-22-14-12(17(21)23-18)10-13(28-3)15(29-4)16(14)30-5/h10,27H,6-9,11H2,1-5H3,(H2,21,22,23) ☒N
  • Key:YNZXWQJZEDLQEG-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

References

edit
  1. van Kalken CK, van der Meulen J, Oe PL, Vriesendorp R, Donker AJ (1986). "Pharmacokinetics of trimazosin and its effects on blood pressure, renal function and proteinuria during short-term therapy of patients with impaired renal function and hypertension". Eur. J. Clin. Pharmacol. 31 (1): 63–8. doi:10.1007/BF00870988. PMID 3780829. S2CID 19123951.
  2. U.S. patent 3,669,968